Torii Pharmaceutical Co Ltd 2023 IR

The report outlines Torii Pharmaceutical's strategic transition to a phase of accelerated growth and its first publication of an Integrated Report for fiscal year 2023. The company achieved net sales of 54.6 billion yen, driven by strong sales of skin disease and allergen products, and updated its VISION2030 net sales target to over 80.0 billion yen. Key milestones included transitioning to a company with an Audit and Supervisory Committee to enhance corporate governance and establishing a new Source Materials Procurement Department to secure cedar pollen supply. Additionally, the company identified eleven material issues and advanced its climate change initiatives by initiating scenario analyses aligned with the TCFD framework.

Company: Torii Pharmaceutical Co Ltd

Sector: Health Care

Country: Japan

Year: 2023

Type: IR

Pages: 55

Back to company

Torii Pharmaceutical Co Ltd

Torii Pharmaceutical Co Ltd 2023 Integrated Report

Integrated Report

The report outlines Torii Pharmaceutical's strategic transition to a phase of accelerated growth and its first publication of an Integrated Report for fiscal year 2023. The company achieved net sales of 54.6 billion yen, driven by strong sales of skin disease and allergen products, and updated its VISION2030 net sales target to over 80.0 billion yen. Key milestones included transitioning to a company with an Audit and Supervisory Committee to enhance corporate governance and establishing a new Source Materials Procurement Department to secure cedar pollen supply. Additionally, the company identified eleven material issues and advanced its climate change initiatives by initiating scenario analyses aligned with the TCFD framework.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2023

Reporting Period

Jan 1, 2023 - Dec 31, 2023

Fiscal Year

2023

Type

Integrated Report

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Total Waste

Women on Board

Women in Management

Employees